Berkshire West Area Prescribing Committee Policy Statement

Drug Name	Secukinumab (Cosentyx®)
Indication under review	First line biologic drug for treating ankylosing spondylitis (AS)
Policy No:	APC 133
Date of Issue:	September 2016
Review Date:	September 2019

Policy Statement:

Secukinumab is recommended as a first line option for treating ankylosing spondylitis in adults whose disease has responded inadequately to conventional treatments (such as NSAIDs) or patients in whom an anti-TNF may not be suitable.

(Please note that patients requiring secukinumab in AS after failure of anti-TNFs are not covered by this policy)

Traffic Light Status	**Red**

Key Points considered:

- Dose considered was 150mg only (funding will not cover doses higher than 150mg)
- This treatment is for biologic naïve patients only. All other patients would require an the completion of an Individual Funding Request form to secure funding.

References:

Baeten D, Siper J et al. Secukinumab an interleukin-17A inhibitor in ankylosing spondylitis. N Eng J Med 2015; 373:2534-48

Date taken to APC:	7th September 2016
Date Ratified by MMC on Behalf of the Board:	21 September 2016